| scholarly article | Q13442814 |
| P50 | author | Todd Golub | Q7812388 |
| Stanley J. Korsmeyer | Q138795 | ||
| Patricia Ernst | Q55155210 | ||
| Andrei Krivtsov | Q55167983 | ||
| Sandra S. Zinkel | Q91232359 | ||
| P2093 | author name string | Jing Wang | |
| Jay L Hess | |||
| Jeffery L Kutok | |||
| Hiromi Iwasaki | |||
| Koichi Akashi | |||
| Scott C Kogan | |||
| Scott A Armstrong | |||
| Phillip G Febbo | |||
| Ema Anastasiadou | |||
| Aaron R Thorner | |||
| Jill K Fisher | |||
| P2860 | cites work | The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9 | Q24317238 |
| Nuclear protein CBP is a coactivator for the transcription factor CREB | Q24319801 | ||
| MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein | Q24550988 | ||
| Coordinate regulation of HOX genes in human hematopoietic cells | Q24564330 | ||
| Targeted oncogene activation by site-specific recombination in transgenic mice | Q24564632 | ||
| Lineage-restricted expression of homeobox-containing genes in human hematopoietic cell lines | Q24603903 | ||
| Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain | Q27860534 | ||
| The CBP co-activator is a histone acetyltransferase | Q28131758 | ||
| Altered Hox expression and segmental identity in Mll-mutant mice | Q29620391 | ||
| The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffolds | Q30956877 | ||
| Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b | Q33889059 | ||
| The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis | Q33891131 | ||
| Evi-2, a common integration site involved in murine myeloid leukemogenesis | Q33933218 | ||
| Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia | Q34488469 | ||
| Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. | Q34733137 | ||
| An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes | Q34733709 | ||
| CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation | Q35901820 | ||
| Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9 | Q35971222 | ||
| MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). | Q36556977 | ||
| MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis | Q37478854 | ||
| Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia | Q38287713 | ||
| MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia | Q38294261 | ||
| Effects of HOX homeobox genes in blood cell differentiation | Q38341754 | ||
| The Oncogene Nup98-HOXA9 Induces Gene Transcription in Myeloid Cells | Q38349193 | ||
| MEIS1 and HOXA7 genes in human acute myeloid leukemia | Q40853987 | ||
| Purification and characterization of mouse hematopoietic stem cells | Q42065991 | ||
| Regulation of activity of the transcription factor GATA-1 by acetylation | Q42823439 | ||
| Binding of p53 to the KIX domain of CREB binding protein. A potential link to human T-cell leukemia virus, type I-associated leukemogenesis | Q45747438 | ||
| The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells | Q47398312 | ||
| Genome‐wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation‐mediated fusion events | Q47973072 | ||
| ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. | Q52510288 | ||
| Chromosomal translocations in human cancer. | Q52512616 | ||
| Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. | Q52548924 | ||
| Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice | Q59064783 | ||
| Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling | Q61910882 | ||
| HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities | Q70458949 | ||
| Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias | Q70905237 | ||
| Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II | Q72656169 | ||
| MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice | Q73086909 | ||
| The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene | Q73374089 | ||
| All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders | Q73516527 | ||
| Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice | Q74314309 | ||
| Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia | Q79291743 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 368-381 | |
| P577 | publication date | 2005-01-06 | |
| P1433 | published in | The EMBO Journal | Q1278554 |
| P1476 | title | Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease | |
| P478 | volume | 24 |
| Q42193771 | A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy |
| Q51147709 | AMKL chimeric transcription factors are potent inducers of leukemia. |
| Q42324390 | Bid protects the mouse hematopoietic system following hydroxyurea-induced replicative stress |
| Q41436188 | Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions |
| Q24297763 | CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis |
| Q38150651 | Cancer genomics identifies disrupted epigenetic genes |
| Q42010591 | Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias |
| Q56965961 | Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4·MLL fusion allele |
| Q26749421 | DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics |
| Q28589003 | Disruption of Sept6, a fusion partner gene of MLL, does not affect ontogeny, leukemogenesis induced by MLL-SEPT6, or phenotype induced by the loss of Sept4. |
| Q34973744 | Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes |
| Q28269627 | Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy |
| Q36991857 | H3K79 methylation profiles define murine and human MLL-AF4 leukemias |
| Q37129652 | HOXA9 is required for survival in human MLL-rearranged acute leukemias |
| Q33374851 | Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders |
| Q36970175 | Hematopoietic developmental pathways: on cellular basis |
| Q51918384 | Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia. |
| Q38777445 | Identification of cooperative genes for E2A-PBX1 to develop acute lymphoblastic leukemia |
| Q49106909 | Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide |
| Q27674674 | Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia |
| Q37962001 | Integrated analysis of genetic and epigenetic alterations in cancer |
| Q33835913 | Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches |
| Q40281320 | MLL chimeric protein activation renders cells vulnerable to chromosomal damage: an explanation for the very short latency of infant leukemia |
| Q35788362 | MLL fusions: pathways to leukemia |
| Q29615368 | MLL translocations, histone modifications and leukaemia stem-cell development |
| Q34113855 | MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. |
| Q24669642 | MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice |
| Q36315585 | Mechanisms of therapy-related carcinogenesis |
| Q36098242 | Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. |
| Q38029260 | Menin as a hub controlling mixed lineage leukemia |
| Q50453702 | Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia |
| Q43285195 | Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation |
| Q33947080 | Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis |
| Q36232545 | Molecular pathogenesis of MLL-associated leukemias |
| Q37995194 | Mouse models as tools to understand and study BCR-ABL1 diseases. |
| Q42383852 | PRDM16 Suppresses MLL1r Leukemia via Intrinsic Histone Methyltransferase Activity |
| Q35541213 | PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway. |
| Q37993742 | Pathways involved in Drosophila and human cancer development: the Notch, Hedgehog, Wingless, Runt, and Trithorax pathway |
| Q39659313 | Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint |
| Q24620829 | Proapoptotic Bid mediates the Atr-directed DNA damage response to replicative stress |
| Q27021749 | Protein lysine acetylation by p300/CBP |
| Q37080843 | Review: genetic models of acute myeloid leukaemia |
| Q24304207 | Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase |
| Q35824823 | Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential |
| Q89169966 | Targeting Epigenetics in Cancer |
| Q92955229 | Targeting chromatin complexes in fusion protein-driven malignancies |
| Q36398751 | Targeting epigenetic regulations in cancer |
| Q26771181 | The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis |
| Q53607290 | The Mll-Een knockin fusion gene enhances proliferation of myeloid progenitors derived from mouse embryonic stem cells and causes myeloid leukaemia in chimeric mice. |
| Q36580114 | The affymetrix GeneChip platform: an overview |
| Q24683173 | The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis |
| Q37863271 | Transcriptional and epigenetic networks in haematological malignancy |
| Q40252270 | Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. |
| Q34235226 | Trithorax group proteins: switching genes on and keeping them active |
| Q48252469 | Tuning Sulfur Oxidation States on Thioether-Bridged Peptide Macrocycles for Modulation of Protein Interactions |
| Q35018755 | Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. |
Search more.